A Concise Review on Novel Drugs Applied in Treatment of Alopecia
February 2025
alopecia Janus kinase inhibitors JAK inhibitors tofacitinib ruxolitinib Deuruxolitinib Ritlecitinib autoimmune-related alopecia areata Wnt signaling pathway platelet-rich plasma PRP therapy stem cell-based interventions hair follicle regeneration follicular microenvironments minoxidil finasteride Rogaine Propecia PRP

TLDR New therapies like JAK inhibitors, PRP, and stem cell treatments show promise for better alopecia management.
The review highlights novel targeted therapies for alopecia, such as Janus kinase (JAK) inhibitors like tofacitinib, ruxolitinib, Deuruxolitinib, and Ritlecitinib, which show promise in treating autoimmune-related alopecia areata by modulating immune responses. Additionally, treatments targeting the Wnt signaling pathway, platelet-rich plasma (PRP) therapy, and stem cell-based interventions are explored for their potential to stimulate hair follicle regeneration and enhance follicular microenvironments. These therapies offer significant advancements over traditional options like minoxidil and finasteride, with improved efficacy and fewer side effects. The review calls for further research to optimize treatment protocols, understand long-term outcomes, and address individual patient variability, suggesting these novel therapies could revolutionize alopecia management.